Supernus Pharmaceuticals (NASDAQ:SUPN) Announces Quarterly Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.48), FiscalAI reports. The firm had revenue of $196.40 million for the quarter, compared to analysts’ expectations of $195.16 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%.

Supernus Pharmaceuticals Trading Up 5.1%

Supernus Pharmaceuticals stock traded up $2.61 during mid-day trading on Tuesday, reaching $53.30. The company’s stock had a trading volume of 2,134,794 shares, compared to its average volume of 726,747. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -156.76, a PEG ratio of 0.64 and a beta of 0.71. Supernus Pharmaceuticals has a twelve month low of $29.16 and a twelve month high of $57.65. The business has a 50 day moving average price of $50.24 and a 200-day moving average price of $48.01.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SUPN. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Bank of America began coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target on the stock. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. Finally, Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $61.60.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, Director Bethany Sensenig sold 4,475 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the sale, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. This represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,185 shares of company stock worth $1,268,022 over the last ninety days. Company insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vestcor Inc bought a new stake in Supernus Pharmaceuticals during the third quarter worth approximately $67,000. EverSource Wealth Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth $51,000. Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth $55,000. Osaic Holdings Inc. grew its holdings in shares of Supernus Pharmaceuticals by 211.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after acquiring an additional 1,328 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Supernus Pharmaceuticals during the third quarter worth $128,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.